Lirafugratinib, also known as RLY-4008, is a tyrosine kinase inhibitor with potential antineoplastic activity. Lirafugratinib binds to and inhibits FGFR2, which results in the inhibition of FGFR2-mediated signal transduction pathways. This inhibits the proliferation of FGFR2-overexpressing tumor cells. FGFR2, a receptor tyrosine kinase upregulated in many tumor cell types, plays a key role in cellular proliferation, migration and survival.
For research use only. We do not sell to patients.
| Name | Lirafugratinib HCl |
|---|---|
| Iupac Chemical Name | N-[4-[4-amino-5-[3-fluoro-4-(4-methylpyrimidin-2-yl)oxyphenyl]-7-methylpyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-2-methylprop-2-enamide;hydrochloride |
| Synonyms | Lirafugratinib Hydrochloride; Lirafugratinib HCl, RLY-4008; RLY 4008; RLY4008; |
| Molecular Formula | C28H25ClFN7O2 |
| Molecular Weight | 546.00 |
| Smile | C=C(C)C(NC1=CC=C(C2=C(C3=CC=C(OC4=NC=CC(C)=N4)C(F)=C3)C5=C(N)N=CN=C5N2C)C=C1)=O.[H]Cl |
| InChiKey | HLGJPRBWELSHLI-UHFFFAOYSA-N |
| InChi | InChI=1S/C28H24FN7O2.ClH/c1-15(2)27(37)35-19-8-5-17(6-9-19)24-22(23-25(30)32-14-33-26(23)36(24)4)18-7-10-21(20(29)13-18)38-28-31-12-11-16(3)34-28;/h5-14H,1H2,2-4H3,(H,35,37)(H2,30,32,33);1H |
| CAS Number | 2688040-45-9 |
| Related CAS |
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | Off-white solid |
|---|---|
| Purity | 98% Min. |
| Storage | Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years). |
| Solubility | Soluble in DMSO |
| Handling | |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| HS Code |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |